Prestige Consumer Opens Its FY2023 With Revenue Thirst Quenched By Hydralyte International Sales
Executive Summary
Hydralyte line has 90% share in Australia’s hydration market and accounted for a large share of firm’s overall sales growth in its latest quarter as 28.9% international sales growth to $34.5m offset flat North American results at $242.4m.
You may also be interested in...
Prestige Consumer’s International Cough/Cold Sales Offset FX Loss In Latest Results
Higher cough/cold OTC sales along with Hydralyte line and sore throat treatments bright spots in October-December offset by COVID-19 and continuing supply chain constraints.
Prestige Consumer Targets Improving Delivering On Demand, Considers Price Hikes As Costs Grow
Around half its reported 4.7% growth to $289.3 million in latest came from price increases. Impact on supply chain continues from problems caused by novel coronavirus pandemic.
US Q3 Consumer Health Earnings Preview: Coming Changes Overshadow Current Conditions?
Rather than reflecting what’s coming in the way of spinoffs, leadership, product approvals or deal closings, firms’ July-September results will reveal influences from inflation and supply chain problems. Like manufacturers across industries, US consumer health product firms are dealing with US currency strengthening and potentially driving down revenues through losses in foreign exchange.